MedTrace Logo

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2025-10-02

Study results available
· View outcomes & findings →

Summary

The Primary Objective was:

-To determine the antitumor activity of SAR444245 in combination with other anticancer therapies.

The Secondary Objectives were:

* To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies.
* To assess other indicators of antitumor activity.
* To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab.
* To assess the immunogenicity of SAR444245.

Conditions

Interventions

DRUG

THOR-707

Intravenous infusion: solution for infusion

DRUG

Pembrolizumab

Intravenous infusion: solution for infusion

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-23
Primary Completion
2023-07-18
Completion
2024-10-17
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Chile
  • France
  • Italy
  • Japan
  • Poland
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914897 on ClinicalTrials.gov